Unpartnered KRAS programs: Data Byte

As proof of concept builds for leading KRAS inhibitors in lung cancer and now other KRAS-mutant tumors, the pipeline of KRAS inhibitors is growing, and they’re almost all unpartnered programs.

It’s been a big year for the long undruggable target. The first inhibitor — Lumakras sotorasib from Amgen Inc. (NYSE:AMGN) — reached the market in May under the accelerated approval pathway for non-small cell lung cancer (NSCLC), and Amgen and Mirati both revealed strong proof of concept in colorectal cancer at this month’s European Society for Clinical Oncology (ESMO) Congress...